Acinetobacter baumannii represents a formidable nosocomial pathogen, largely due to its rapid acquisition of multidrug resistance and its capacity to cause severe infections. This Gram‐negative ...

November 4, 2009 (Philadelphia, Pennsylvania) — Multidrug-resistant (MDR) Acinetobacter baumannii (ACBA) is a persistent threat to hospitalized patients, whether the infection is acquired in the ...

A research team has discovered a fundamental mechanism that helps the dreaded hospital pathogen Acinetobacter baumannii to survive. This mechanism explains why the pathogen is difficult to eradicate ...

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems ...

Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by ...

Jaipur: A study conducted by SMS Medical College has raised alarm bells as it reveals a significant rise in antibiotic resistance among Acinetobacter bacteria infections. The research, which analysed ...

Chinese Academy of Medical Sciences has divulged imidazopyridine derivatives reported to be useful for the treatment of Acinetobacter infections, particularly A. baumannii infections.

BioWorld - Monday, December 1, 2025 Breaking News: Trump administration impacts continue to roil the life sciences sector See today's BioWorld Science Home » Agents for Acinetobacter infections named ...

Bacteria learned to survive by developing their own defence mechanism against antibiotic use, finds a 2025 study report by ...

New research has shown that a lack of dietary zinc can boost the chances of a lung infection caused by Acinetobacter baumannii bacteria; these pathogens are a major reason why people on ventilators ...